Medicare Guideline - Hematuria Workup & Bladder Cancer Management

Medicare POC Policy Set · effective 2026-01-01 · version v1

← Back to all guidelines

Metadata

Doc IDguideline::medicare::hematuria_bladder_cancer_v1

PayerMedicare

Payer Slugmedicare

Topichematuria bladder cancer

Document Typepayer_guideline

Chunks5

Covered ICD Codes (7)

R31.0 R31.29 C67.9 C67.2 C68.9 N32.0 N32.3

Procedure Keywords (9)

cystoscopy TURBT transurethral resection of bladder tumor urine cytology CT urogram intravesical BCG therapy bladder biopsy blue-light cystoscopy radical cystectomy

Guideline Chunks (5)

Each chunk has its own embedding and is independently retrievable

guideline::medicare::hematuria_bladder_cancer_v1#chunk0

Section: Coverage intent · Length: 187 chars

Cystoscopic evaluation, biopsy, transurethral resection (TURBT), and adjunctive therapy may be considered medically necessary in the workup and management of hematuria and bladder cancer.

guideline::medicare::hematuria_bladder_cancer_v1#chunk1

Section: Clinical indications that support medical necessity · Length: 473 chars

1. Gross hematuria (ICD R31.0) without alternative explanation. 2. Microscopic hematuria (ICD R31.29) with risk factors (age over 35, smoking history, occupational exposure). 3. Confirmed bladder cancer (ICD C67.9, C67.2) requiring resection, surveillance, or adjuvant therapy. 4. Urothelial carcinoma (ICD C68.9) of any urinary tract site. 5. Bladder outlet obstruction (ICD N32.0) with diagnostic uncertainty. 6. Bladder diverticulum (ICD N32.3) with associated symptoms.

guideline::medicare::hematuria_bladder_cancer_v1#chunk2

Section: Documentation requirements · Length: 290 chars

1. Urinalysis and urine cytology results. 2. Imaging report (CT urogram, MRI, ultrasound) when available. 3. Smoking history and occupational risk factors. 4. Prior cystoscopy results if performed. 5. Pathology report for confirmed cancer cases. 6. Cancer staging (TNM) for malignant cases.

guideline::medicare::hematuria_bladder_cancer_v1#chunk3

Section: Potential reasons for denial or pend · Length: 243 chars

1. Microscopic hematuria without risk factors and no prior workup. 2. Repeat cystoscopy outside surveillance interval guidelines. 3. Missing pathology or imaging documentation. 4. Requested staging procedure outside oncology protocol timeline.

guideline::medicare::hematuria_bladder_cancer_v1#chunk4

Section: Decision logic · Length: 389 chars

Likely eligible when gross hematuria is documented, or microscopic hematuria with risk factors is present, or when surveillance interval matches NCCN bladder cancer guidelines. Manual review when hematuria is microscopic without clear risk factors. Likely not eligible when no urinalysis confirms hematuria or surveillance frequency exceeds guideline recommendations without justification.